News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
John R. Stuelpnagel, a Director at 10x Genomics, Inc. (NASDAQ:TXG), sold a total of 20,000 shares of Class A Common Stock on August 11, 2026. The sales were conducted in two open-market transactions, with 17,000 shares sold at a weighted average price of $57.5812 …
10x Genomics (TXG) has been a significant winner for Hedgeye, with its stock price soaring over 157% since May 19 due to strong Signal Strength, favorable macroeconomic "Quads," and robust fundamental performance. The company recently reported strong second-quarter results, raised full-year guidance, and despite …
This article provides financial information for 10x Genomics Inc Class A (BMV:TXG) on TradingView. It specifically highlights the company's enterprise value to EBIT forward metric. The content appears to be a stub or a placeholder page within a larger financial data platform.
This article first appeared on GuruFocus. Release Date: August 07, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Production is on track to meet annual guidance, with Q2 being the lowest quarter and …
Key Points Interested in 10x Genomics? Here are five stocks we like better. Atera demand is strong ahead of launch: Booked orders by the end of Q2 exceeded the approximately 40 systems 10x Genomics expects to ship in 2026, with production capacity—not demand—currently limiting …
10x Genomics TXG reported a second-quarter 2026 loss of 14 cents per share against earnings of 28 cents in the year-ago quarter, representing a 150% year-over-year decline. Still, the figure beat the Zacks Consensus Estimate of a loss of 23 cents by 38.1%. Revenues …
Strong free cash flow and 46% AISC margin support continued capital returns, with higher production expected in H2 as grades improve (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - Torex Gold Resources Inc. (the "Company" …
Earnings Call Insights: 10x Genomics (TXG) Q2 2026 MANAGEMENT VIEW * "Revenue for the second quarter was $151 million" (CEO Serge Saxonov) and management highlighted a nonrecurring item: "we recognized $1.6 million of license and royalty revenue in connection with our settlement with Takara" …
10x Genomics reported a Q2 2026 total revenue of $151.0M, a 13% decrease from Q2 2025, primarily due to the absence of large, non-recurring patent-license settlements from the previous year. Despite this, underlying products and services revenue grew by 3% to $149.1M, driven by …
This Yahoo Finance page provides a comprehensive overview of 10x Genomics, Inc. (TXG), including its current stock price, recent news, chart performance over various periods, and key financial data. The article details the company's products and services, such as the Chromium and Visium platforms …
Search by ticker symbol or company name and select a result to open its chart.